Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18338812 | 0.97 | CA3 (0.54) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL23069642 | 0.94 | CA12 (0.50) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL8958360 | 0.91 | KDM4E (0.43) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL20536196 | 0.90 | CA3 (0.43) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL20536003 | 0.90 | CA2 (0.43) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL4555815 | 0.88 | PAOX (0.63) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL13842143 | 0.88 | CA12 (0.52) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL16246838 | 0.88 | CA12 (0.52) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL18874871 | 0.86 | CA3 (0.45) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL719437 | 0.86 | CA12 (0.54) | CA3CA5ACA5BCA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3271423-B1 | CATIONIC DIRECT DYES | BASF SE (DE) | 2022-08-31 | — | — | EP | disclosed |
| US-20210087337-A1 | COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | VYOME THERAPEUTICS LIMITED (IN) | 2021-03-25 | — | — | US | disclosed |
| EP-3507325-A2 | COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | Vyome Therapeutics Limited (IN) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018042367-A2 | COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2018-03-08 | — | — | WO | disclosed |
| US-8440643-B2 | Inhibitors of beta-lactamase | METHYLGENE INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CA3 3852/4885CA5A 3237/4885CA5B 2940/4885 |
| US-20210087337-A1 | COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | CUTA, GMPS, MMP8 | CA3 4877/4885CA5A 4679/4885CA5B 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.